ID

33105

Descrição

Study ID: 104021 Clinical Study ID: 104021 Study Title: A phase III, partially blind, randomized study to evaluate the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ Tritanrix™-HepB and GSK Biologicals Kft’s DTPw-HBV vaccines as compared to concomitant administration of Commonwealth Serum Laboratory’s (CSL’s) DTPw (Triple Antigen™) and GSK Biologicals’ HBV (Engerix™-B), when co-administered with GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine, to healthy infants at 3, 4½ and 6 months of age, after a birth dose of hepatitis B vaccine. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00158756 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: Hepatitis B Vaccine, Recombinant Trade Name: Engerix B Study Indication: Hepatitis B

Palavras-chave

Versões (1)
  1. 28/11/2018 28/11/2018 -
Titular dos direitos

GSK group of companies

Transferido a

28 de novembro de 2018

DOI

Para um pedido faça login.

Licença

Creative Commons BY-NC 3.0
Comentários do modelo :

Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.

Voltar para os comentários do modelo
Comentários do grupo de itens para :

Comentários do item para :

Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.

Immunogenicity of co-administration of Tritanrix™-HepB and DTPw-HBV vaccines or Triple Antigen™ and Engerix™-B with HRV vaccine to infants (3, 4½ and 6 month) - 104021

Inglês

Elimination Criteria (Study Eligibility)

1 Formulários  
Elimination Criteria during the Study
Descrição

Elimination Criteria during the Study

Check below "Yes" for all that apply
Descrição

The following criteria should be checked at each visit subsequent to the first visit. If any become applicable during the study, it will not require withdrawal of the subject from the study but may determine a subject's evaluability in the according-to-protocol analysis

Tipo de dados

text

A. Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) during the study period.
Descrição

A. Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) during the study period.

Tipo de dados

boolean

B. Chronic administration (more than 14 days) of immunosuppressants or other immunomodifying drugs during the study period.
Descrição

For corticosteroids, this mean prednisone, or equivalent, >=0.5 mg/kg/day. Inhaled and topical steroids are allowed

Tipo de dados

boolean

C. Administration of a vaccine not foreseen by the study protocol during the period starting from 30 days before each dose of vaccine(s) and ending 30 days after, with the exception of OPV.
Descrição

C. Administration of a vaccine not foreseen by the study protocol during the period starting from 30 days before each dose of vaccine(s) and ending 30 days after, with the exception of OPV.

Tipo de dados

boolean

D. Administration of immunoglobulins and/or any blood products during the study period.
Descrição

D. Administration of immunoglobulins and/or any blood products during the study period.

Tipo de dados

boolean

Voltar ao início da página

Similar models

Elimination Criteria (Study Eligibility)

1 Formulários
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Item Group
Elimination Criteria during the Study
Check below "Yes" for all that apply
Item
Check below "Yes" for all that apply
text
A. Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) during the study period.
Item
A. Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) during the study period.
boolean
B. Chronic administration (more than 14 days) of immunosuppressants or other immunomodifying drugs during the study period.
Item
B. Chronic administration (more than 14 days) of immunosuppressants or other immunomodifying drugs during the study period.
boolean
C. Administration of a vaccine not foreseen by the study protocol during the period starting from 30 days before each dose of vaccine(s) and ending 30 days after, with the exception of OPV.
Item
C. Administration of a vaccine not foreseen by the study protocol during the period starting from 30 days before each dose of vaccine(s) and ending 30 days after, with the exception of OPV.
boolean
D. Administration of immunoglobulins and/or any blood products during the study period.
Item
D. Administration of immunoglobulins and/or any blood products during the study period.
boolean
Voltar ao início da página 

Contacto

Use este formulário para feedback, perguntas e sugestões de aperfeiçoamento.

Campos marcados com * são obrigatórios.

Ajuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial